2003
DOI: 10.1007/s00216-003-2140-6
|View full text |Cite
|
Sign up to set email alerts
|

Chemical and analytical characterization of related organic impurities in drugs

Abstract: A system is proposed for the classification of related organic impurities in drugs and drug products including among others (separated and non-separated) intermediates, various kinds of by-products, among them products of different side reactions, epimeric/diastereomeric, enantiomeric impurities, impurities in natural products, and finally degradation products. Examples are taken mainly from the author's own experience and from among the named impurities in the European Pharmacopoeia with focus on impurities i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2006
2006
2017
2017

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 50 publications
(3 citation statements)
references
References 35 publications
0
3
0
Order By: Relevance
“…Preparation of small molecules of pharmaceutical interest can result in low molar fraction impurities that stem from unreacted starting materials or intermediates, products from competing side reactions and degraded or modified catalysts. 13 Because these diverse minor components may have unintended metabolic effects, impurities must be quantified and if present in sufficient molar excess, removed or structurally identified and shown to be biologically inert. 13 In proteomics, protein modifications can be indicative of biological activity as well as provide biomarkers for disease.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Preparation of small molecules of pharmaceutical interest can result in low molar fraction impurities that stem from unreacted starting materials or intermediates, products from competing side reactions and degraded or modified catalysts. 13 Because these diverse minor components may have unintended metabolic effects, impurities must be quantified and if present in sufficient molar excess, removed or structurally identified and shown to be biologically inert. 13 In proteomics, protein modifications can be indicative of biological activity as well as provide biomarkers for disease.…”
Section: Introductionmentioning
confidence: 99%
“…13 Because these diverse minor components may have unintended metabolic effects, impurities must be quantified and if present in sufficient molar excess, removed or structurally identified and shown to be biologically inert. 13 In proteomics, protein modifications can be indicative of biological activity as well as provide biomarkers for disease. 48 Quantitation of these discrete modifications can be used to determine relative expression levels in living systems.…”
Section: Introductionmentioning
confidence: 99%
“…[1][2][3][4][5][6][7] The impurities present in API can be process impurities, degradation impurities or impurities originating from raw materials used in the synthesis. [8][9][10][11] The structural elucidation of an unknown impurity is a complex procedure. The conventional approach to the impurity identification consists of separation of the impurity from the main component followed by isolation and multiple spectroscopic analysis and/or analysis by other standard techniques such as x-ray crystallography and mass spectrometry (MS) of the isolated impurity.…”
Section: Introductionmentioning
confidence: 99%